

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

REGENERON PHARMACEUTICALS, INC.,  
Petitioner,

v.

NOVARTIS PHARMA AG,  
NOVARTIS TECHNOLOGY LLC,  
NOVARTIS PHARMACEUTICALS CORPORATION,  
Patent Owner.

---

Case No. IPR2020-01317  
U.S. Patent No. 9,220,631

---

**PETITIONER'S UPDATED MANDATORY NOTICES  
PURSUANT TO 37 C.F.R. § 42.8**

Petitioner Regeneron Pharmaceuticals, Inc. hereby submits its updated mandatory notices pursuant to 37 C.F.R. § 42.8(a)(3).

**A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) - Unchanged**

The real party-in-interest is Regeneron Pharmaceuticals, Inc.

**B. Related Matters (37 C.F.R. § 42.8(b)(2)) - Updated**

On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC filed a complaint at the U.S. International Trade Commission alleging that Petitioner infringes claims 1-6 and 11-26 of U.S. Patent No. 9,220,631 (the '631 Patent), and that a domestic industry exists with respect to claims 1-10 and 14-26 of the '631 Patent. On the same day, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC filed a complaint in the United States District Court for the Northern District of New York alleging that Petitioner infringes at least claim 1 of the '631 Patent (N.D.N.Y. 1:20-cv-00690-TJM-CFH).

On July 16, 2020, Petitioner filed the following petitions for *inter partes* review against the '631 Patent: IPR2020-01317 and IPR2020-01318.

On July 17, 2020, Petitioner filed a complaint in the United States District Court for the Southern District of New York against Novartis Pharma AG, Novartis Technology LLC, Novartis Pharmaceuticals Corporation (collectively "Novartis"), and Vetter Pharma International GmbH ("Vetter") (S.D.N.Y. 1:20-cv-

00502-AJN). The complaint seeks judgment that (i) Novartis's and Vetter's conduct violates Section 1 of the Sherman Act, 15 U.S.C. § 1; (ii) Novartis's conduct violates Section 2 of the Sherman Act, 15 U.S.C. § 2; and (iii) the '631 Patent be declared unenforceable. The complaint also seeks damages and injunctive relief restraining and enjoining Novartis and Vetter from continuing the unlawful conduct in violation of the Sherman Act.

**C. Lead and Back-Up Counsel and Service Information (37 C.F.R. § 42.8(b)(3)-(4)) - Unchanged**

Petitioner identifies the following lead and back-up counsel and service information:

<p><u>Lead Counsel</u> Elizabeth Stotland Weiswasser Weil, Gotshal &amp; Manges LLP 767 Fifth Avenue New York, NY 10153 T: 212-310-8022 F: 212-310-8007 elizabeth.weiswasser@weil.com USPTO Reg. No. 55,721</p>	<p><u>Back-Up Counsel</u> Anish R. Desai Weil, Gotshal &amp; Manges LLP 767 Fifth Avenue New York, NY 10153 T: 212-310-8730 F: 212-310-8007 anish.desai@weil.com USPTO Reg. No. 73,760</p> <p>Natalie Kennedy Weil, Gotshal &amp; Manges LLP 767 Fifth Avenue New York, NY 10153 T: 212-310-8730 F: 212-310-8007 natalie.kennedy@weil.com USPTO Reg. No. 68,511</p> <p>Andrew Gesior Weil, Gotshal &amp; Manges LLP</p>
---	---

767 Fifth Avenue  
New York, NY 10153  
T: 212-310-8730  
F: 212-310-8007  
andrew.gesior@weil.com  
USPTO Reg. No. 76,588

Brian E. Ferguson  
Weil, Gotshal & Manges LLP  
2001 M Street, N.W., Suite 600  
Washington, D.C. 20036  
T: 202-682-7000  
F: 202-857-0940  
brian.ferguson@weil.com  
USPTO Reg. No. 36,801

Christopher M. Pepe  
Weil, Gotshal & Manges LLP  
2001 M Street, N.W., Suite 600  
Washington, D.C. 20036  
T: 202-682-7000  
F: 202-857-0940  
christopher.pepe@weil.com  
USPTO Reg. No. 73,851

Please address all correspondence to lead and backup counsel. Petitioner consents to service by electronic mail at the following address:

[Regeneron.IPR.Service@weil.com](mailto:Regeneron.IPR.Service@weil.com).

Date: July 28, 2020

Respectfully submitted,

*/Elizabeth Stotland Weiswasser /*

Elizabeth Stotland Weiswasser

Reg. No. 55,721

Lead Counsel for Petitioner

Weil, Gotshal & Manges LLP

767 Fifth Avenue

New York, NY 10153

T: 212-310-8022

[elizabeth.weiswasser@weil.com](mailto:elizabeth.weiswasser@weil.com)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.